Tetracycline Inhibitors
2 drugsAbout Tetracycline
Tetracycline is a broad-spectrum polyketide antibiotic that inhibits bacterial protein synthesis. While its precise molecular mechanism is still being investigated, it remains a valuable therapeutic agent against a wide range of bacterial infections.
Tetracycline represents a well-established drug target with a history of clinical use. There is currently no genetic evidence directly linking Tetracycline to specific diseases, but its clinical efficacy supports continued development.
Two FDA-approved drugs include Tetracycline: PYLERA and BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE. Both drugs are small molecules and are classified within the 'other' therapeutic area.
Top Tetracycline Drugs
The competitive landscape includes LABS JUVISE and PH HEALTH, each with approved drugs.
The presence of only two companies suggests a relatively unconcentrated market with potential entry opportunities.
Tetracycline Drug Modality Landscape
Modalities
Routes of Administration
Tetracycline is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like modified peptides or biologics could provide a competitive advantage.
Tetracycline Clinical Trials 121 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Tetracycline. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 11 | 1 | 0 | 92% |
| Phase 2 | 28 | 16 | 2 | 10 | 89% |
| Phase 3 | 26 | 20 | 2 | 4 | 91% |
| Phase 4 | 55 | 40 | 7 | 8 | 85% |
Top Sponsors
By Modality
Top Conditions
Tetracycline Drug Approval Timeline (2006 - 2023)
Helicobacter pylori Infection
The first drug was approved in 2006 (PYLERA), with the most recent approval in 2023.
The 18-year span between approvals suggests sustained interest, but also potential saturation in the therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 86 (18 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Tetracycline. A trial counts if an approved drug acting on Tetracycline is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.